Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501715 | 1.00 | HRH3 (0.48) | HRH3KDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL502016 | 1.00 | HRH3 (0.48) | HRH3KDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL501637 | 0.98 | HRH3 (0.52) | HRH3KDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL10852700 | 0.98 | HRH3 (0.52) | HRH3KDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL720901 | 0.98 | HRH3 (0.52) | HRH3KDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL501546 | 0.98 | HRH3 (0.52) | HRH3KDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL64198 | 0.91 | HRH3 (0.44) | HRH3KDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL12371266 | 0.91 | HRH3 (0.51) | HRH3ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL5487629 | 0.91 | KDM4E (0.43) | KDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL1277024 | 0.90 | HRH3 (0.54) | HRH3ALDH1A1KMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2023225050-A1 | HIGH-DIELECTRIC CONSTANT ZWITTERIONIC LIQUIDS | THE PENN STATE RESEARCH FOUNDATION (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2022093817-A1 | MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS, AND METHODS OF MAKING AND USING SAME | YALE UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3267794-B1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10336721-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180179176-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2018-06-28 | — | — | US | disclosed |
| EP-2457898-A1 | FULLERENE DERIVATIVE | Sumitomo Chemical Company Limited (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20120111411-A1 | FULLERENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120111411-A1 | FULLERENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20110202328-A1 | System for the determination of selective absorbent molecules through predictive correlations | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110202328-A1 | System for the determination of selective absorbent molecules through predictive correlations | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2011-08-18 | — | — | US | disclosed |
| CN-101663790-A | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same | MITSUBISHI CHEM CORP | 2010-03-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336721-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | MIF, MMP12, CSF1R | HRH3 2066/4885KDM4E 3312/4885HTT 4753/4885 |
| US-20180179176-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | MIF, MMP12, CSF1R | HRH3 2066/4885KDM4E 3312/4885HTT 4753/4885 |
| US-20120111411-A1 | FULLERENE DERIVATIVE | HCN2, KCNN2, TMEM109 | HRH3 4728/4885KDM4E 3338/4885HTT 1946/4885 |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | MIF, MMP12, METAP1 | HRH3 3657/4885KDM4E 689/4885HTT 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.